Biocartis Group NV (BCART) - Product Pipeline Analysis, 2024 Update

Summary

Biocartis Group NV (Biocartis) is a molecular diagnostics company. It provides diagnostic solutions for oncology and infectious disease tests. The company offers oncology tests, infectious disease tests, oncology research assays. Biocartis offers oncology test kits including genefusion panel, EGFR mutation test, BRAF mutation test, mutation test, NRAS-BRAF mutation test, MSI test, hepatopredict, colonode, hepatopredict, merlin assay. The company carries out Idylla platform that offers tests for melanoma, colorectal and lung cancer. The company has operations in the US and Belgium. Biocartis is headquartered in Mechelen, Flanders, Belgium.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Biocartis Group NV
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Reasons to Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Biocartis Group NV Company Overview
Biocartis Group NV Company Snapshot
Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview
Biocartis Group NV - Pipeline Analysis Overview
Biocartis Group NV - Key Facts
Biocartis Group NV - Major Products and Services
Biocartis Group NV Pipeline Products by Development Stage
Biocartis Group NV Pipeline Products Overview
APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay
APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay Product Overview
EGFR Colon Cancer Test
EGFR Colon Cancer Test Product Overview
Idylla - EGFR/BRAF+ Test
Idylla - EGFR/BRAF+ Test Product Overview
Idylla ABC Assay
Idylla ABC Assay Product Overview
Idylla Blood Stream Infections Panel
Idylla Blood Stream Infections Panel Product Overview
Idylla Brain Cancer Assay
Idylla Brain Cancer Assay Product Overview
Idylla Companion Diagnostic Assay
Idylla Companion Diagnostic Assay Product Overview
Idylla EGFR CDx Assay
Idylla EGFR CDx Assay Product Overview
Idylla Endometrium Assay
Idylla Endometrium Assay Product Overview
Idylla Endpoint CDx Test
Idylla Endpoint CDx Test Product Overview
Idylla Extended KRAS Mutation Test
Idylla Extended KRAS Mutation Test Product Overview
Idylla Extended NRAS Mutation Test
Idylla Extended NRAS Mutation Test Product Overview
Idylla Hematology Assay
Idylla Hematology Assay Product Overview
Idylla HPV Test - Head And Neck Cancer
Idylla HPV Test - Head And Neck Cancer Product Overview
Idylla Immuno Tx Panel Test
Idylla Immuno Tx Panel Test Product Overview
Idylla Meningitis Assay
Idylla Meningitis Assay Product Overview
Idylla MERS Assay
Idylla MERS Assay Product Overview
Idylla MSI CDx
Idylla MSI CDx Product Overview
Idylla Neuro Panel Test
Idylla Neuro Panel Test Product Overview
Idylla NGS Prep Panel - Lung
Idylla NGS Prep Panel - Lung Product Overview
Idylla NRAS-BRAF Mutation Test
Idylla NRAS-BRAF Mutation Test Product Overview
Idylla Oncotype DX Prostate
Idylla Oncotype DX Prostate Product Overview
Idylla Resistance Monitoring Assay
Idylla Resistance Monitoring Assay Product Overview
Idylla Retrieve - NGS Hotspot Panel Assay
Idylla Retrieve - NGS Hotspot Panel Assay Product Overview
Idylla SARS-CoV-2 Test
Idylla SARS-CoV-2 Test Product Overview
Idylla SARS-CoV2/Flu/RSV Panel
Idylla SARS-CoV2/Flu/RSV Panel Product Overview
Idylla Sepsis Assay
Idylla Sepsis Assay Product Overview
Idylla Syndromic Immunocompromised Panel
Idylla Syndromic Immunocompromised Panel Product Overview
Idylla Syndromic Panel - Tropical Fever
Idylla Syndromic Panel - Tropical Fever Product Overview
Idylla System - Multiplex Companion Diagnostics Test
Idylla System - Multiplex Companion Diagnostics Test Product Overview
Idylla Test - Cell Therapy Monitoring
Idylla Test - Cell Therapy Monitoring Product Overview
Idylla Viral Load Assay - HBV
Idylla Viral Load Assay - HBV Product Overview
Idylla Viral Load Assay - HCV
Idylla Viral Load Assay - HCV Product Overview
Idylla Viral Load Assay - HIV
Idylla Viral Load Assay - HIV Product Overview
SeptiCyte Triage
SeptiCyte Triage Product Overview
Biocartis Group NV - Key Competitors
Biocartis Group NV - Key Employees
Biocartis Group NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Biocartis Group NV, Recent Developments
Oct 23, 2024: Biocartis Announces Six Idylla Abstracts to be Presented at AMP 2024 Annual Meeting
May 06, 2024: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
Oct 20, 2023: Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla Presented at European Society of Molecular Oncology Congress (ESMO)
Aug 10, 2023: Biocartis Partners With Lilly to Explore Biomarker Testing for NSCLC Patients Using the Idylla Platform
May 12, 2023: Biocartis Group announces results of the annual shareholders meeting held on 12 May 2023
Mar 02, 2023: Biocartis announces the US FDA 510(k) clearance for the Idylla MSI Test
Jan 17, 2023: Biocartis Group NV: Biocartis meets 2022 key objectives
Nov 08, 2022: New Idylla EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients
Nov 08, 2022: New Idylla EGFR study shows reduction of time-to-treatment by 48% for lung cancer patients
Oct 31, 2022: Biocartis announces nine Idylla studies to be published at upcoming AMP 2022 annual meeting
Appendix
Methodology
About the Publisher
Contact the Publisher
Disclaimer

List of Tables

Biocartis Group NV Pipeline Products and Ongoing Clinical Trials Overview
Biocartis Group NV Pipeline Products by Equipment Type
Biocartis Group NV Pipeline Products by Indication
Biocartis Group NV, Key Facts
Biocartis Group NV, Major Products and Services
Biocartis Group NV Number of Pipeline Products by Development Stage
Biocartis Group NV Pipeline Products Summary by Development Stage
APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay - Product Status
APIS Breast Cancer Subtyping Test With Idylla PIK3CA-AKT1 Mutation Assay - Product Description
EGFR Colon Cancer Test - Product Status
EGFR Colon Cancer Test - Product Description
Idylla - EGFR/BRAF+ Test - Product Status
Idylla - EGFR/BRAF+ Test - Product Description
Idylla ABC Assay - Product Status
Idylla ABC Assay - Product Description
Idylla Blood Stream Infections Panel - Product Status
Idylla Blood Stream Infections Panel - Product Description
Idylla Brain Cancer Assay - Product Status
Idylla Brain Cancer Assay - Product Description
Idylla Companion Diagnostic Assay - Product Status
Idylla Companion Diagnostic Assay - Product Description
Idylla EGFR CDx Assay - Product Status
Idylla EGFR CDx Assay - Product Description
Idylla Endometrium Assay - Product Status
Idylla Endometrium Assay - Product Description
Idylla Endpoint CDx Test - Product Status
Idylla Endpoint CDx Test - Product Description
Idylla Extended KRAS Mutation Test - Product Status
Idylla Extended KRAS Mutation Test - Product Description
Idylla Extended NRAS Mutation Test - Product Status
Idylla Extended NRAS Mutation Test - Product Description
Idylla Hematology Assay - Product Status
Idylla Hematology Assay - Product Description
Idylla HPV Test - Head And Neck Cancer - Product Status
Idylla HPV Test - Head And Neck Cancer - Product Description
Idylla Immuno Tx Panel Test - Product Status
Idylla Immuno Tx Panel Test - Product Description
Idylla Meningitis Assay - Product Status
Idylla Meningitis Assay - Product Description
Idylla MERS Assay - Product Status
Idylla MERS Assay - Product Description
Idylla MSI CDx - Product Status
Idylla MSI CDx - Product Description
Idylla Neuro Panel Test - Product Status
Idylla Neuro Panel Test - Product Description
Idylla NGS Prep Panel - Lung - Product Status
Idylla NGS Prep Panel - Lung - Product Description
Idylla NRAS-BRAF Mutation Test - Product Status
Idylla NRAS-BRAF Mutation Test - Product Description
Idylla Oncotype DX Prostate - Product Status
Idylla Oncotype DX Prostate - Product Description
Idylla Resistance Monitoring Assay - Product Status
Idylla Resistance Monitoring Assay - Product Description
Idylla Retrieve - NGS Hotspot Panel Assay - Product Status
Idylla Retrieve - NGS Hotspot Panel Assay - Product Description
Idylla SARS-CoV-2 Test - Product Status
Idylla SARS-CoV-2 Test - Product Description
Idylla SARS-CoV2/Flu/RSV Panel - Product Status
Idylla SARS-CoV2/Flu/RSV Panel - Product Description
Idylla Sepsis Assay - Product Status
Idylla Sepsis Assay - Product Description
Idylla Syndromic Immunocompromised Panel - Product Status
Idylla Syndromic Immunocompromised Panel - Product Description
Idylla Syndromic Panel - Tropical Fever - Product Status
Idylla Syndromic Panel - Tropical Fever - Product Description
Idylla System - Multiplex Companion Diagnostics Test - Product Status
Idylla System - Multiplex Companion Diagnostics Test - Product Description
Idylla Test - Cell Therapy Monitoring - Product Status
Idylla Test - Cell Therapy Monitoring - Product Description
Idylla Viral Load Assay - HBV - Product Status
Idylla Viral Load Assay - HBV - Product Description
Idylla Viral Load Assay - HCV - Product Status
Idylla Viral Load Assay - HCV - Product Description
Idylla Viral Load Assay - HIV - Product Status
Idylla Viral Load Assay - HIV - Product Description
SeptiCyte Triage - Product Status
SeptiCyte Triage - Product Description
Biocartis Group NV, Key Employees
Biocartis Group NV, Subsidiaries
Glossary

List of Figures

Biocartis Group NV Pipeline Products by Equipment Type
Biocartis Group NV Pipeline Products by Development Stage

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Galapagos NV
Oxurion NV
ERC Belgium SA
Celyad Oncology SA
DMS Imaging SA

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€741EUR$750USD£616GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€1481EUR$1,500USD£1,233GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€2222EUR$2,250USD£1,849GBP